Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway-mediated diseases.

To selectively modulate human complement alternative pathway (CAP) activity implicated in a wide range of acute and chronic inflammatory conditions and to provide local cell surface and tissue-based inhibition of complement-induced damage, we developed TT30, a novel therapeutic fusion protein linking the human complement receptor type 2 (CR2/CD21) C3 fragment (C3frag = iC3b, C3dg, C3d)-binding domain with the CAP inhibitory domain of human factor H (fH). TT30 efficiently blocks ex vivo CAP-dependent C3frag accumulation on activated surfaces, membrane attack complex (MAC) formation and hemolysis of RBCs in a CR2-dependent manner, and with a ∼ 150-fold potency gain over fH, without interference of C3 activation or MAC formation through the classic and lectin pathways. TT30 protects RBCs from hemolysis and remains bound and detectable for at least 24 hours. TT30 selectively inhibits CAP in cynomolgus monkeys and is bioavailable after subcutaneous injection. Using a unique combination of targeting and effector domains, TT30 controls cell surface CAP activation and has substantial potential utility for the treatment of human CAP-mediated diseases.

[1]  S. Perkins,et al.  Self-association and domain rearrangements between complement C3 and C3u provide insight into the activation mechanism of C3. , 2010, The Biochemical journal.

[2]  M. Kirschfink,et al.  Therapeutic complement inhibition: new developments. , 2010, Seminars in thrombosis and hemostasis.

[3]  P. Zipfel,et al.  Complement regulators and inhibitory proteins , 2009, Nature Reviews Immunology.

[4]  G. Gilkeson,et al.  A targeted inhibitor of the alternative complement pathway reduces angiogenesis in a mouse model of age-related macular degeneration. , 2009, Investigative ophthalmology & visual science.

[5]  O. Llorca,et al.  3D structure of the C3bB complex provides insights into the activation and regulation of the complement alternative pathway convertase , 2009, Proceedings of the National Academy of Sciences.

[6]  C. Atkinson,et al.  A Novel Targeted Inhibitor of the Alternative Pathway of Complement and Its Therapeutic Application in Ischemia/Reperfusion Injury1 , 2008, The Journal of Immunology.

[7]  V. M. Holers,et al.  The spectrum of complement alternative pathway‐mediated diseases , 2008, Immunological reviews.

[8]  M. Harboe,et al.  The alternative complement pathway revisited , 2008, Journal of cellular and molecular medicine.

[9]  John D Lambris,et al.  Complement-targeted therapeutics , 2007, Nature Biotechnology.

[10]  R. Brodsky,et al.  Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria , 2007, Nature Biotechnology.

[11]  G. Bleck.  An Alternative Method for the Rapid Generation of Stable, High-Expressing Mammalian Cell Lines , 2006 .

[12]  Thomas Walz,et al.  Structural transitions of complement component C3 and its activation products , 2006, Proceedings of the National Academy of Sciences.

[13]  Piet Gros,et al.  Structure of C3b reveals conformational changes that underlie complement activity , 2006, Nature.

[14]  S. Bureeva,et al.  Drug design using the example of the complement system inhibitors' development. , 2005, Drug discovery today.

[15]  Piet Gros,et al.  Structures of complement component C3 provide insights into the function and evolution of immunity , 2005, Nature.

[16]  John D Lambris,et al.  Synthetic small-molecule complement inhibitors. , 2004, Current opinion in investigational drugs.

[17]  S. Narayana,et al.  Structural analysis of engineered Bb fragment of complement factor B: insights into the activation mechanism of the alternative pathway C3-convertase. , 2004, Molecular cell.

[18]  Stephen Tomlinson,et al.  Complement receptor 2-mediated targeting of complement inhibitors to sites of complement activation. , 2003, The Journal of clinical investigation.

[19]  V. Holers,et al.  The complement system as a therapeutic target in autoimmunity. , 2003, Clinical immunology.

[20]  H. Petty,et al.  Function of the Lectin Domain of Mac-1/Complement Receptor Type 3 (CD11b/CD18) in Regulating Neutrophil Adhesion1 , 2002, The Journal of Immunology.

[21]  John D Lambris,et al.  Epitope Mapping Using the X-Ray Crystallographic Structure of Complement Receptor Type 2 (CR2)/CD21: Identification of a Highly Inhibitory Monoclonal Antibody That Directly Recognizes the CR2-C3d Interface1 , 2001, The Journal of Immunology.

[22]  D. Hourcade,et al.  Functional domains, structural variations and pathogen interactions of MCP, DAF and CR1. , 2000, Immunopharmacology.

[23]  John D Lambris,et al.  Complement inhibitors: a resurgent concept in anti-inflammatory therapeutics. , 2000, Immunopharmacology.

[24]  John D Lambris,et al.  Therapeutic Interventions in the Complement System , 2000, Contemporary Immunology.

[25]  D. Fearon.  The complement system and adaptive immunity. , 1998, Seminars in immunology.

[26]  S. Makrides.  Therapeutic inhibition of the complement system. , 1998, Pharmacological reviews.

[27]  D. Lublin,et al.  Identification of complement regulatory domains in human factor H. , 1995, Journal of immunology.

[28]  V. Holers,et al.  Analysis of Epstein-Barr virus-binding sites on complement receptor 2 (CR2/CD21) using human-mouse chimeras and peptides. At least two distinct sites are necessary for ligand-receptor interaction. , 1991, The Journal of biological chemistry.

[29]  B. Myones,et al.  Structural requirements for C3d,g/Epstein-Barr virus receptor (CR2/CD21) ligand binding, internalization, and viral infection. , 1990, The Journal of biological chemistry.

[30]  R. Wallis,et al.  Paths reunited: Initiation of the classical and lectin pathways of complement activation. , 2010, Immunobiology.

[31]  Piet Gros,et al.  Complement driven by conformational changes , 2008, Nature Reviews Immunology.

[32]  C. Atkinson,et al.  A complement inhibitor specifically targeted to sites of complement activation effectively ameliorates collagen-induced arthritis in dba/1J mice , 2007 .

[33]  Hector MolinaS,et al.  Analysis of Epstein-Barr Virus-binding Sites on Complement Receptor 2 ( CR 2 / CD 21 ) Using Human-Mouse Chimeras and Peptides , 2001 .